Theratechnologies (TSE:TH) Sets New 52-Week Low at $3.83

Theratechnologies Inc (TSE:TH)’s stock price reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as C$3.83 and last traded at C$3.85, with a volume of 92400 shares trading hands. The stock had previously closed at C$3.96.

TH has been the topic of a number of analyst reports. Royal Bank of Canada decreased their price objective on Theratechnologies from C$7.00 to C$6.00 and set a “sector perform” rating on the stock in a research note on Wednesday, October 9th. National Bank Financial decreased their price objective on Theratechnologies from C$8.25 to C$7.00 and set a “sector perform” rating on the stock in a research note on Wednesday, October 9th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of C$8.75.

The company has a debt-to-equity ratio of 167.71, a quick ratio of 1.94 and a current ratio of 2.51. The company has a market capitalization of $304.73 million and a P/E ratio of -43.15. The business has a 50 day moving average of C$4.70 and a 200-day moving average of C$5.60.

Theratechnologies (TSE:TH) last posted its earnings results on Tuesday, October 8th. The company reported C($0.03) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of C($0.04) by C$0.01. The business had revenue of C$21.30 million for the quarter, compared to analysts’ expectations of C$23.97 million. As a group, equities analysts forecast that Theratechnologies Inc will post 0.07 EPS for the current fiscal year.

In other Theratechnologies news, Director Dale Weil bought 10,500 shares of Theratechnologies stock in a transaction that occurred on Tuesday, October 15th. The stock was acquired at an average cost of C$4.84 per share, for a total transaction of C$50,866.20. Following the completion of the transaction, the director now directly owns 10,500 shares in the company, valued at C$50,866.20.

Theratechnologies Company Profile (TSE:TH)

Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.

Further Reading: Producer Price Index (PPI)

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with's FREE daily email newsletter.